• ̍̍ CSE: BRAX
  • ̍̍ OTC: BRAXF
  • ̍̍ FWB: 4960

H.C. Wainwright

September 12, 2022

Braxia Scientific to Present at H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022

TORONTO, ONTARIO September 9, 2022 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, is pleased to announce its participation at the H.C. Wainwright Global Annual Global Investment Conference being held in New York, September 12-14, 2022. CEO Dr. Roger McIntyre will present virtually during the conference providing a update on its recently acquired U.S. based telemedicine business, KetaMD, as well as its progress expanding the clinical research infrastructure required to execute on the Company’s growing pipeline of registered clinical trials alongside third-party sponsors. The on-demand session will be available at 7:00 a.m. ET Monday September 12, 2022. Dr. McIntyre will also be available to host one-on-one meetings with institutional investors registered with H.C. Wainwright.   About Braxia...

June 27, 2022

Braxia Scientific CEO to Deliver Keynote Address at H.C. Wainwright & Co. 1st Annual Mental Health Conference

See the full press release Webcast Replay Link: Click here for secure access

September 23, 2021

Global Investment Conference

H.C. Wainwright 23rd Annual Global Investment Conference – September 13-15, 2021 Registration for H.C. Wainwright 23rd Annual Global Investment Conference – September 13-15, 2021 Click here Symbols – CSE: BRAX  OTC: BRAXF  FWB: 496

June 17, 2021

Dr. Roger McIntyre @ H.C. Wainwright Virtual Conference Presentation

The Patient Experience and Commercial Considerations When Launching Psychoactive Agents in Psychiatry